Hepatic lesions induced by drugs include extremely diverse various clinical, biological and histological manifestations that can determine acute or chronic hepatobiliary disease. The term of hepatitis is recommended to be used when there is a histological confirmation. In the last decades a 11 time increase of the hepatic lesions induced by drugs is reported, due both to the increase of the number of used drugs but also by their more frequent recognition.
We carried out a combined retrospective study and longitudinally prospective study that included patients with drug hepatitis. In our study there were 83 cases of drug hepatitis at AINS, which represents 33.46 % of the total number of 248 patients with drug hepatitis. In our study the highest drug hepatitis at AINS were Nimesulid (24 cases), followed by Diclofenac (21 cases), and the fewest at Piroxicam (9 cases). All the cases from the study were symptomatic, showing the increase of the cytolysis enzymes and sometimes cholestasis enzymes (mainly GGT).
The average age at diagnosis was 60.1 years for the 248 patients, being lower for the male gender (57.47 years), compared to the female gender (61.26 years). Women were affected in the highest degree, 69.35% being women and 30.64% men. In our study drug hepatitis by hepatic cytolysis was dominant, more frequent than the cholestatic ones.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Fernández-Villar A. Sopeña B. Vázquez R. Ulloa F. Fluiters E. Mosteiro M. César M.- V. & Piñeiro L. (2003). Isoniazid Hepatotoxicity among Drug Users: The Role of Hepatitis C. Clinical Infectious Diseases. 36(3) 293-298. doi:
1. Fernández-Villar, A., Sopeña, B., Vázquez, R., Ulloa, F., Fluiters, E., Mosteiro, M., César, M.- V. & Piñeiro, L. (2003). Isoniazid Hepatotoxicity among Drug Users: The Role of Hepatitis C. Clinical Infectious Diseases. 36(3), 293-298. doi: 10.1086/345906.)| false
3. Huang Y.S. Chern H.D. Su W.J. Wu J.C. Lai S.L. Yang S.Y. Chang F.Y. & Lee S.D. (2002). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 35(4) 883-889. doi:
5. Steele M.A. Burk R.F. & DesPrez R.M. (1991). Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest. 99(2) 465-471.
6. Yew W.W. & Leung C.C. (2007). Antituberculosis Drugs anbd Hepatotoxicity. Hong Kong Medical Diary 12(1) 7-9
7. de Abajo F.J. Montero D. Madurga M. & Garcia Rodriguez L.A. (2004). Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 58(1) 71-80. doi:
7. de Abajo, F.J., Montero, D., Madurga, M. & Garcia Rodriguez, L.A. (2004). Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 58(1), 71-80. doi: 10.1111/j.1365-2125.2004.02133.x)| false
8. Jobanputra P. Amarasena R. Maggs F. Homer D. Bowman S. Rankin E. Filer A. Raza K. & Jubb R. (2008). Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 9 48. doi:
8. Jobanputra, P., Amarasena, R., Maggs, F., Homer, D., Bowman, S., Rankin, E., Filer, A., Raza, K. & Jubb, R. (2008). Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. BMC Musculoskelet Disord. 9, 48. doi: 10.1186/1471-2474-9-48)| false
9. Emery P. Breedveld F.C. Lemmel E.M. Kaltwasser J.P. Dawes P.T. Gomor B. Van Den Bosch F. Nordstrom D. Bjorneboe O. Dahl R. Horslev-Petersen K. Rodriguez De La Serna A. Molloy M. Tikly M. Oed C. Rosenburg R. & Loew-Friedrich I. (2000). A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford). 39(6) 655-665.
10. Matteson E. & Cush J.J. (2001). Reports of leflunomide hepatotoxicity in patients with rheumatoid arthritis. ACR Hotline
11. Cohen S.B. & Iqbal I. (2003). Leflunomide. Int J Clin Pract. 57(2) 115-120.
12. Strand V. Cohen S. Schiff M. Weaver A. Fleischmann R. Cannon G. Fox R. Moreland L. Olsen N. Furst D. Caldwell J. Kaine J. Sharp J. Hurley F. & Loew-Friedrich I. (1999). Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 159(21) 2542-2550.